Tak-220

Catalog No. :
ACEXHL013
CAS No. :
333994-00-6
Molecular Formula :
C31H41ClN4O3
Molecular Weight :
553.15

IUPAC Name:1-acetyl-N-(3-(4-(4-carbamoylbenzyl)piperidin-1-yl)propyl)-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide

Tak-220 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg98%$224.00Login to see priceInquiryInquiry
5mg98%$523.00Login to see priceInquiryInquiry
10mg98%$746.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameTak-220
IUPAC Name1-acetyl-N-(3-(4-(4-carbamoylbenzyl)piperidin-1-yl)propyl)-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
Molecular FormulaC31H41ClN4O3
Molecular Weight553.15
SMILESO=C(C1CCN(C(C)=O)CC1)N(CCCN2CCC(CC3=CC=C(C(N)=O)C=C3)CC2)C4=CC=C(C)C(Cl)=C4
InChI KeyASSJTMUEFHUKMJ-UHFFFAOYSA-N
Synonym1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]-1-piperidyl]propyl]-N-(3-chloro-4-methyl-phenyl)piperidine-4-carboxamide | CS-5579 | A913339 | 1-acetyl-N-(3-{4-((4-carbamoylphenyl)methyl)piperidin-1-yl}propyl)-N-(3-chloro-4-methylphenyl)piperidine-4-carboxam
CAS No.333994-00-6
PubChem CID5275766

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACEXHL013 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEXHL013 route product structure diagram
    ACEXHL013333994-00-6
Inquiry

2. ACEXHL013 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEXHL013 route product structure diagram
    ACEXHL013333994-00-6
Inquiry

Comments (0)